ABANZA successfully completed its Pre-Series A funding round, raising $5 million. Proceeds will be used to accelerate the U.S. launch of ABANZA’s soft tissue repair product line, including the WasherCap and WasherCap Mini.
ABANZA’s technology addresses major challenges in the soft tissue repair market by enhancing fixation strength regardless of patient bone quality and minimizing graft displacement after surgery.
The WasherCap Fixation System has received FDA clearance for fixation of soft tissue grafts, including tendons and ligaments, during surgical procedures such as ACL reconstruction and is currently in preliminary launch. The company is also preparing to introduce the WasherCap Mini, which will cater to a wider range of applications including knee, hand, wrist and elbow repairs.
Juan Abascal, CEO of ABANZA, commented, “This funding represents a pivotal moment for our entry into the U.S. market with the WasherCap Soft Tissue Fixation System. The WasherCap product is the first in a series of innovative solutions we plan to introduce for soft tissue repair. We are fortunate to have engaged with an outstanding group of investors, many of whom bring deep healthcare expertise and valuable connections to our venture.”
ABANZA successfully completed its Pre-Series A funding round, raising $5 million. Proceeds will be used to accelerate the U.S. launch of ABANZA's soft tissue repair product line, including the WasherCap and WasherCap Mini.
ABANZA's technology addresses major challenges in the soft tissue repair market by enhancing fixation strength regardless...
ABANZA successfully completed its Pre-Series A funding round, raising $5 million. Proceeds will be used to accelerate the U.S. launch of ABANZA’s soft tissue repair product line, including the WasherCap and WasherCap Mini.
ABANZA’s technology addresses major challenges in the soft tissue repair market by enhancing fixation strength regardless of patient bone quality and minimizing graft displacement after surgery.
The WasherCap Fixation System has received FDA clearance for fixation of soft tissue grafts, including tendons and ligaments, during surgical procedures such as ACL reconstruction and is currently in preliminary launch. The company is also preparing to introduce the WasherCap Mini, which will cater to a wider range of applications including knee, hand, wrist and elbow repairs.
Juan Abascal, CEO of ABANZA, commented, “This funding represents a pivotal moment for our entry into the U.S. market with the WasherCap Soft Tissue Fixation System. The WasherCap product is the first in a series of innovative solutions we plan to introduce for soft tissue repair. We are fortunate to have engaged with an outstanding group of investors, many of whom bring deep healthcare expertise and valuable connections to our venture.”
Copy to clipboard 
